KYLE MACHYNIA: Open Payments
NPI 1851848956 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$61,224 in 297 payments from 19 companies in 2025. Trend: 2023 $8,795 · 2024 $42,391 · 2025 $61,224
Speaker / faculty: $41,668Travel & lodging: $7,231Food & beverage: $7,064Consulting: $5,098Education: $163
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 62 | $33,271 |
| Galderma Laboratories, L.P. | 24 | $9,052 |
| ABBVIE INC. | 47 | $7,882 |
| Lilly USA, LLC | 22 | $4,015 |
| GENZYME CORPORATION | 19 | $2,299 |
| E.R. Squibb & Sons, L.L.C. | 9 | $954 |
| SANOFI US SERVICES INC. | 1 | $823 |
| Novartis Pharmaceuticals Corporation | 15 | $460 |
| Incyte Corporation | 27 | $423 |
| Regeneron Healthcare Solutions, Inc. | 12 | $402 |
Products named: TREMFYA, NEMLUVIO, RINVOQ, SKYRIZI, EBGLYSS, DUPIXENT, AYVAKIT, OPZELURA.
Industry payments across NV — which companies pay providers there.
